Allogene Therapeutics Inc.
News
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Ticker Report Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) have received an average rating of "Moderate Buy" from the eleven analysts that are currently covering the stock, MarketBeat...\n more…
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
Zacks Investment Research A month has gone by since the last earnings report for Allogene Therapeutics (ALLO). Shares have added about 6.4% in that time frame, outperforming the S&P 500.Will the recent positive trend continue...\n more…
Rothschild Investment LLC Acquires Shares of 22,200 Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Ticker Report Rothschild Investment LLC bought a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) in the second quarter, according to its most recent disclosure with the Securities &...\n more…
Q3 2024 Earnings Estimate for Allogene Therapeutics, Inc. (NASDAQ:ALLO) Issued By Zacks Research
Zolmax Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at Zacks Research raised their Q3 2024 earnings estimates for Allogene Therapeutics in a report released on Wednesday, August...\n more…
Q3 2024 Earnings Estimate for Allogene Therapeutics, Inc. (NASDAQ:ALLO) Issued By Zacks Research
Ticker Report Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Analysts at Zacks Research raised their Q3 2024 earnings estimates for Allogene Therapeutics in a report released on Wednesday, August 28th...\n more…
Q3 2024 Earnings Forecast for Allogene Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:ALLO)
Ticker Report Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) - Equities research analysts at HC Wainwright lifted their Q3 2024 earnings estimates for shares of Allogene Therapeutics in a research report...\n more…